Factors Predicting the Efficacy of Adefovir Dipivoxil on Treatment-Naive Chronic Hepatitis B Patients at 48 Weeks
Gut and Liver
; : 478-485, 2011.
Article
en En
| WPRIM
| ID: wpr-56818
Biblioteca responsable:
WPRO
ABSTRACT
BACKGROUND/AIMS: To reveal possible factors predicting the effect of adefovir dipivoxil (ADV) treatment on chronic hepatitis B (CHB) and optimize the utilization of ADV. METHODS: In total, 168 treatment-naive CHB patients were enrolled, including 117 hepatitis B e antigen (HBeAg)-positive patients and 51 HBeAg-negative patients who met the inclusion criteria. All patients were treated with ADV 10 mg per day for 48 weeks. Multiple logistic regression analyses were used to investigate baseline factors, and responses at weeks 12 and 24 were analyzed as predictive values. RESULTS: Multiple regression analyses showed that baseline HBeAg status and HBV DNA levels significantly affected the virological response (VR) (p or =10(3) copies/mL at week 24 is observed.
Palabras clave
Texto completo:
1
Índice:
WPRIM
Asunto principal:
ADN
/
Adenina
/
Índice de Masa Corporal
/
Modelos Logísticos
/
Hepatitis B Crónica
/
Organofosfonatos
/
Hepatitis B
/
Antígenos e de la Hepatitis B
/
Hepatitis Crónica
Tipo de estudio:
Prognostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Gut and Liver
Año:
2011
Tipo del documento:
Article